Comparison analysis
bereum, a company specializing in heat-killed lactic acid bacteria postbiotics, and Dx&Vx, a bio-health care company, signed an MOU on April 5th. Through this agreement, the two companies plan to target the microbiome market by conducting joint research, such as analyzing not only lactic acid bacteria but also various microorganisms in the intestine.
The signing ceremony for the memorandum of understanding (MOU) took place at Bereum's headquarters in Wonju. Attendees included Bereum CEO Han Kwon-il and research director Shin Hyun-dong, as well as Dx&Vx research director Park Sang-jin and director Lee Dong-ha.
bereum is a company that has been researching and developing postbiotics based on the microbiome for over 30 years. In 2015, the company was recognized as the first high-tech venture business in the food sector by the Ministry of Economy and Finance, and in 2020, received the Excellent Patent Award in Korea. Using its technology, bereum is conducting clinical trials to evaluate the effectiveness of postbiotics, including a study on the effects of postbiotics on overweight and obese adults in India, as well as a joint project with Yonsei University Severance Hospital and the Ministry of Trade, Industry and Energy to develop clinical treatment for inflammatory bowel disease based on human-derived microbiome.
Dx&Vx (CEO Park Sang-tae) is a bio-healthcare company specialized in microbiome research. Above all, the Microbiome Research Center has the expertise in molecular genomics analysis technology, functional microbe discovery, process development know-how, and finished product development equipment, and is progressively advancing its technology.
Microbiome, which the two companies are focusing on, combined word for the microorganisms (microbes) and their ecosystem (biome) that reside in the human body, including the vast number of microbes and their genetic information. Recently, various studies have revealed the relationship between gut microbiota and diseases, leading to increased global interest in this field.
Both companies are accelerating their efforts to pioneer the microbiome market, starting with basic research on the Berem postbiotics strain. Berem's excellent physiologically active strains, such as EF-2001 and beLP1, will be analyzed using Dx&Vx's strength in bioinformatics to study their effects and efficacy on human diseases and health. In addition, since the composition of gut microbiota varies from person to person, it is expected that gut microbiome analysis could lead to the development of personalized diagnostic kits.
Han Kwon-il, CEO of bereum, said, "We expect that this agreement will serve as a platform for creating meaningful results in the microbiome market based on the core capabilities of both companies," and added, "We will spare no support to expedite smooth collaboration."